CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages

Mechanisms of lymphoma clearance induced by high-dose alkylating agents

(2019) Chen Lossos et al.   Cancer Discovery

CD4+ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models

(2019) Bjarne Bogen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD4+ T cell-mediated rejection of MHC class II-positive tumor cells is dependent on antigen secretion and indirect presentation on host APCs

(2018) Ole Audun Werner Haabeth et al.   CANCER RESEARCH

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens

(2017) Michael S. Khodadoust et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma

(2017) Xinyi Chen et al.   Oncotarget

Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens

(2015) A. A. Tveita et al.   CANCER RESEARCH

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival

(2015) C. M. Reed et al.   CLINICAL CANCER RESEARCH

Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma

(2015) S Panchabhai et al.   LEUKEMIA

Idiotype-specific CD4+ T cells eradicate disseminated myeloma

(2015) O A Haabeth et al.   LEUKEMIA

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

Indirect CD4+T-cell-mediated elimination of MHC IINEGtumor cells is spatially restricted and fails to prevent escape of antigen-negative cells

(2014) Anders A. Tveita et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

(2014) Ole Audun Werner Haabeth et al.   Frontiers in Immunology

Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen

(2014) Anders Aune Tveita et al.   OncoImmunology

Tumor-associated macrophages as a prognostic parameter in multiple myeloma

(2013) Elif Suyanı et al.   ANNALS OF HEMATOLOGY

Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment

(2013) Simona Berardi et al.   Journal of Oncology

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice

(2012) K. B. Lorvik et al.   BLOOD

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells

(2012) Jaehyup Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease

(2012) Peter O. Hofgaard et al.   PLoS One

A model for cancer-suppressive inflammation

(2012) Ole Audun Werner Haabeth et al.   OncoImmunology

M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells

(2011) M. Heusinkveld et al.   JOURNAL OF IMMUNOLOGY

Is Secretion of Tumour-specific Antigen Important for Cancer Eradication by CD4+ T Cells? - Implications for Cancer Immunotherapy by Adoptive T Cell Transfer

(2011) A. Corthay et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer

(2011) Ole Audun Werner Haabeth et al.   Nature Communications

Bystander killing of cancer requires the cooperation of CD4+and CD8+T cells during the effector phase

(2010) Andrea Schietinger et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

(2010) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

(2009) Y. Zheng et al.   BLOOD

Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells

(2009) A. Corthay et al.   CANCER RESEARCH